Filing Flows › GSK (GSK) › Q2 2026
GSK (GSK) Q2 2026 earnings results (second quarter 2026)
6-K filed Sep 8, 2026
GSK (GSK) reported revenue of $8.4B for the second quarter 2026 (Q2 2026), +5% from a year earlier. Operating margin was 5.7%, net earnings $435M (5.2% of revenue).
GSK, Q2 2026: revenue $8.4B (+5% year over year), operating margin 5.7%, net earnings $435M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $8.4B | — | +5% |
| Gross profit | $6.1B | — | +6% |
| Operating profit | $481M | — | -76% |
| Net earnings | $435M | — | -70% |
What changed
Revenue was £8.4B in Q2 2026, up 5% year over year. HIV was the largest line at 25% of revenue.
Gross margin was 73.1%, up 0.2 points from a year earlier. Operating profit was £0.48B, a 5.7% margin (down 19.6 points year over year). Operating profit fell £1.5B even though revenue rose £0.42B versus a year earlier, so costs grew faster than sales. Operating expenses grew 49% against revenue growth of 5%. The fastest-growing cost line was Research & development (+71%). Net earnings were £0.43B, down 70% year over year. The effective tax rate was -56.2%.
Questions
What was GSK's revenue in the second quarter 2026?
GSK (GSK) reported revenue of $8.4B for the second quarter 2026 (Q2 2026), +5% from a year earlier.
Was GSK profitable in the second quarter 2026?
Operating profit was $481M (5.7% of revenue) and net earnings $435M.
Source: GSK 6-K on SEC EDGAR.